Additionally, annexins included in the pathways upregulated in iVSMCs have been linked to cardiovascular disease and identified as having therapeutic potential (ANXA1, ANXA2) [76,77,78,79]. This evidence concerns the gene ANXA1 and cardiovascular disorder.